Progenics Pharmaceuticals Inc. Hits New 52-Week High at $6.56 (PGNX)
Shares of Progenics Pharmaceuticals (NASDAQ:PGNX) hit a new 52-week high on Monday, American Banking News.com reports. The company traded as high as $6.56 and last traded at $6.31, with a volume of 1,383,332 shares trading hands. The stock had previously closed at $6.10.
Progenics Pharmaceuticals has a one year low of $2.53 and a one year high of $6.47. The stock’s 50-day moving average is $5.06 and its 200-day moving average is $4.94. The company’s market cap is $392.1 million.
Progenics Pharmaceuticals (NASDAQ:PGNX) last issued its quarterly earnings data on Monday, November 11th. The company reported ($0.17) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.22) by $0.05. The company had revenue of $0.90 million for the quarter, compared to the consensus estimate of $2.00 million. During the same quarter in the prior year, the company posted ($0.33) earnings per share. The company’s quarterly revenue was down 18.2% on a year-over-year basis. On average, analysts predict that Progenics Pharmaceuticals will post $-0.85 earnings per share for the current fiscal year.
Progenics Pharmaceuticals, Inc (NASDAQ:PGNX) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.